Drugs / LB-102
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04588129 | Jan → Sep 2021 | schizophrenia | LB Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT06179108 | Nov 2023 → Dec 2024 | schizophrenia | LB Pharmaceuticals Inc. | Completed | Met primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT07369154 | Apr 2026 → Dec 2028 expected | schizophrenia | LB Pharmaceuticals Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07363577 | Mar 2026 → Jun 2027 expected | schizophrenia | LB Pharmaceuticals Inc. | Recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT04187560 Comparator | Jan → Jul 2020 | schizophrenia | LB Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT07494305 Comparator | Jan 2026 → Feb 2028 expected | bipolar I disorder | LB Pharmaceuticals Inc. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LB-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07494305 ↗ |
| Known as | N-Methyl amisulpride | “LB-102 (N-Methyl amisulpride) formulated capsule will be administered orally once daily for one day in 4 subjects.” NCT04588129 ↗2“LB-102 (N-methyl amisulpride) is a novel benzamide under investigation for the treatment of schizophrenia.” PMID 42018313 ↗ Jul 2026 “LB-102 N-Methyl amisulpride)” NCT04187560 ↗ |
| Action | Inhibit | “LB-102 is a dopamine D2/3 and 5HT7 antagonist.” NCT06179108 ↗ |
| Modality | Small molecule | “LB-102 (N-methyl amisulpride) is a novel benzamide under investigation for the treatment of schizophrenia.” PMID 42018313 ↗ Jul 2026 |
| Route | Oral | “LB-102 Administered Orally” NCT04187560 ↗ |